Research has shown that certain drugs increase older adults’ risk of falls — a leading cause of serious injury and death for people 65 years and older — but what about their impact, specifically, on people with dementia?
Although older adults with dementia face much greater risk of falling, information is lacking on how some of the most widely prescribed drugs may contribute to these adverse events. The Adult Changes in Thought (ACT) study, which has been following a population of Kaiser Permanente Washington patients since 1986, was developed to find ways to prevent or delay dementia and to promote healthy aging. ACT also has served as a rich data source for various research-in-aging investigations, including evaluation of potential risks of medication use in older adults.
A new study, published in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, used ACT data to provide one of the most extensive analyses to date on the associations between a variety of central nervous system-active medications and injuries from falls in older adults with dementia.
To understand the study’s implications, we posed six questions to the paper’s lead author, Laura Hart, PharmD, MS, an assistant clinical professor at University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, who led the research while a geriatrics pharmacy fellow at the University of Washington School of Pharmacy.
Laura Hart: Central nervous system (CNS)-active medications are medications that have effects in the brain and/or spinal cord. Many CNS-active medications have been associated with adverse effects, including falls, in the older adult population. These medications include antidepressants, anticholinergics, antipsychotics, benzodiazepines, sedatives/hypnotics, and opioids. It is especially important to address risks of these medications in older adults with dementia given a high prevalence of use in this population. In addition, there is evidence to suggest that older adults with dementia may be more sensitive to some of the effects of these medications.
LH: We found that current use of CNS-active medications was associated with an increased risk of fall-related injury, which includes fracture, dislocation, or head injury.
LH: Our results reinforce the importance of cautious use and close monitoring of CNS-active medications in older adults with dementia. It is important for clinicians to address medication use as part of a comprehensive effort to prevent falls, carefully weighing the risks versus benefits of a given medication.
LH: Using data from the ACT study allowed us to evaluate CNS-active medication use in a population with a gold-standard research diagnosis of dementia. We were also able to examine subjects starting from the time of dementia onset, which had not been done in previous studies. In addition, we were able to evaluate how dose and number of CNS-active medications used may influence risk of falls. Further, using ACT data allowed us to strengthen our methodology by better accounting for potential confounding factors in our analyses.
LH: We were surprised that a clear dose-response relationship was not detected. However, it is important to note that increased risk was found even at low doses and across different dose levels. We also evaluated the number of medication classes used and found that risk was elevated across all our use categories: one medication class, two medication classes, or three or more medication classes. While we found a trend of increasing risk with greater number of concurrent medication classes, it did not quite achieve statistical significance.
LH: One key question to further explore is how risk of falls associated with CNS-active medication use in older adults with dementia may change over time following dementia onset. In addition, it is important to further evaluate which specific medication classes may pose the greatest risk for falls in this population.
The study, “The Association Between Central Nervous System-Active Medication Use and Fall-Related Injury in Community-Dwelling Older Adults with Dementia,” was published online March 12 in the journal Pharmacotherapy. In addition to Dr. Hart, the paper has five co-authors: Zachary Marcum, PhD, PharmD, and Shelly Gray, PharmD, MS, of UW School of Pharmacy, Rod Walker, MS, of Kaiser Permanente Washington Health Research Institute (KPWHRI); Paul Crane, MD, MPH, of UW Division of General Internal Medicine; and Eric Larson, MD, MPH, of KPWHRI, Kaiser Permanente Washington, and UW Division of General Internal Medicine. Drs. Crane and Larson are the co-principal investigators of the ACT study.